Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Tofacitinib in reducing inflammation in the sacroiliac joints and
spine on magnetic resonance imaging (MRI) in patients with active Psoriatic Arthritis (PsA)
with axial Involvement (BASDAI [Bath Ankylosing Spondylitis Disease Activity Index] ≥ 4 and
total backpain ≥ 4 despite treatment with NSAIDs plus evidence of active inflammation in the
sacroiliac joints or spine on MRI).